Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 163 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease February 1, 2022 On your marks, get set… start-up! August 13, 2021 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Load more HOT NEWS FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... Utility of Genomic Profiling Use for Targeted Therapy in a Phase... Reflecting On My Time As the Cancer.Net Editor in Chief 2020 round-up: Our biggest cancer stories of the year
